Capricor Therapeutics (CAPR) Upgraded at Zacks Investment Research

Capricor Therapeutics (NASDAQ:CAPR) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Tuesday. The brokerage presently has a $2.00 price target on the biotechnology company’s stock. Zacks Investment Research‘s price target points to a potential upside of 2.56% from the stock’s current price.

According to Zacks, “Capricor Therapeutics, Inc. is a biotechnology company. It is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two drug candidates in development: Cenderitide and CU-NP. Capricor Therapeutics, Inc., formerly known as Nile Therapeutics, Inc., is based in San Mateo, California. “

Separately, HC Wainwright reiterated a “buy” rating and issued a $8.60 price objective (up previously from $6.50) on shares of Capricor Therapeutics in a report on Friday, January 26th.

Shares of Capricor Therapeutics (CAPR) traded up $0.15 during mid-day trading on Tuesday, reaching $1.95. The company had a trading volume of 918,396 shares, compared to its average volume of 639,093. Capricor Therapeutics has a 12 month low of $0.63 and a 12 month high of $4.25. The stock has a market capitalization of $44.48, a price-to-earnings ratio of -2.95 and a beta of -3.90.

Institutional investors and hedge funds have recently bought and sold shares of the business. Belpointe Asset Management LLC bought a new position in Capricor Therapeutics in the third quarter worth $249,000. Jane Street Group LLC bought a new position in shares of Capricor Therapeutics during the third quarter valued at $190,000. Wells Fargo & Company MN bought a new position in shares of Capricor Therapeutics during the third quarter valued at $107,000. Virtu KCG Holdings LLC increased its holdings in shares of Capricor Therapeutics by 571.9% during the second quarter. Virtu KCG Holdings LLC now owns 179,301 shares of the biotechnology company’s stock valued at $149,000 after acquiring an additional 152,614 shares in the last quarter. Finally, Brown Advisory Inc. bought a new position in shares of Capricor Therapeutics during the fourth quarter valued at $1,796,000. Institutional investors and hedge funds own 4.05% of the company’s stock.

WARNING: “Capricor Therapeutics (CAPR) Upgraded at Zacks Investment Research” was originally published by American Banking News and is the property of of American Banking News. If you are reading this story on another domain, it was copied illegally and republished in violation of US & international trademark & copyright laws. The legal version of this story can be read at

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.

Get a free copy of the Zacks research report on Capricor Therapeutics (CAPR)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply